Cambricon(SH:688256) Sou Hu Cai Jing·2025-05-01 03:21Core Viewpoint - The company, Cambrian Biotech (寒武纪-U), has announced a plan to issue A-shares to specific investors, aiming to raise up to 498 million RMB for projects related to large model chip platforms, software platforms, and to supplement working capital [1][2]. Fundraising Details - The total amount to be raised is capped at 498 million RMB, with specific allocations of 290 million RMB for the chip platform project, 160 million RMB for the software platform project, and 48 million RMB for working capital [1][2]. - The issuance will target no more than 35 specific investors, including various financial institutions and qualified individual investors [2][3]. Issuance Process - The final list of investors will be determined after approval from the Shanghai Stock Exchange and registration by the China Securities Regulatory Commission (CSRC) [3]. - Shares will be subscribed in cash at a price not lower than 80% of the average trading price over the previous 20 trading days [4]. Share Quantity and Control - The number of shares issued will not exceed 2,087,283.7 shares, representing a maximum of 5% of the company's total shares prior to the issuance [5][7]. - The company's controlling shareholder, Chen Tian Shi, currently holds 28.63% of the shares directly and an additional 7.34% through a partnership, totaling 35.97% voting rights, which will not change post-issuance [6][7]. Historical Context - Cambrian Biotech was listed on the Shanghai Stock Exchange on July 20, 2020, and has previously raised funds through public offerings, with the last issuance in 2022 raising approximately 1.67 billion RMB [8][9][10]. - The company has not distributed dividends since its listing [11].